Close

Roth Remains Positive on Ligand Pharma (LNGD) Following New Licensing Agreement with Avion Pharma

August 14, 2014 10:57 AM EDT Send to a Friend
Roth Capital affirms its Buy rating and $92 target price on Ligand Pharmaceuticals (Nasdaq: LGND) following news earlier that the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login